Endocrine Abstracts

Prostate cancer (PCa) is one of the leading causes of cancer deaths among men population worldwide. This tumour pathology is commonly diagnosed through the determination of serum PSA levels. However, the diagnostic capability of PSA dramatically drops when considering patients with PSA levels lower than 10 ng/ml, the so-called “grey-zone”1. Therefore, additional non-invasive diagnostic biomarkers are urgently needed to substitute/complement PSA. In this se...

Background: Prostate cancer (PCa) diagnosis is based on the serum levels of prostatic specific antigen (PSA), which might be influenced by many clinical conditions, including obesity. In addition, the diagnostic capability of PSA test dramatically drops when considering patients with PSA levels lower than 10ng/mL (i.e. “grey-zone”). Therefore, the identification of more reliable non-invasive diagnostic biomarkers for PCa is a critical unmet clinical need. In this sce...